CARDIOL THERAPEUTICS INC-A (CRDL.CA) Fundamental Analysis & Valuation

TSX:CRDL • CA14161Y2006

Current stock price

1.93 CAD
+0.05 (+2.66%)
Last:

This CRDL.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. CRDL.CA Profitability Analysis

1.1 Basic Checks

  • CRDL had negative earnings in the past year.
  • CRDL had a negative operating cash flow in the past year.
  • In the past 5 years CRDL always reported negative net income.
  • CRDL had a negative operating cash flow in each of the past 5 years.
CRDL.CA Yearly Net Income VS EBIT VS OCF VS FCFCRDL.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

  • CRDL's Return On Assets of -268.65% is on the low side compared to the rest of the industry. CRDL is outperformed by 90.63% of its industry peers.
  • Looking at the Return On Equity, with a value of -363.82%, CRDL is doing worse than 84.38% of the companies in the same industry.
Industry RankSector Rank
ROA -268.65%
ROE -363.82%
ROIC N/A
ROA(3y)-80.54%
ROA(5y)-81.5%
ROE(3y)-102.38%
ROE(5y)-100.84%
ROIC(3y)N/A
ROIC(5y)N/A
CRDL.CA Yearly ROA, ROE, ROICCRDL.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CRDL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRDL.CA Yearly Profit, Operating, Gross MarginsCRDL.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K -40K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. CRDL.CA Health Analysis

2.1 Basic Checks

  • CRDL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CRDL.CA Yearly Shares OutstandingCRDL.CA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CRDL.CA Yearly Total Debt VS Total AssetsCRDL.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • CRDL has an Altman-Z score of 6.59. This indicates that CRDL is financially healthy and has little risk of bankruptcy at the moment.
  • CRDL's Altman-Z score of 6.59 is amongst the best of the industry. CRDL outperforms 90.63% of its industry peers.
  • A Debt/Equity ratio of 0.01 indicates that CRDL is not too dependend on debt financing.
  • CRDL has a better Debt to Equity ratio (0.01) than 84.38% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 6.59
ROIC/WACCN/A
WACCN/A
CRDL.CA Yearly LT Debt VS Equity VS FCFCRDL.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

  • A Current Ratio of 3.89 indicates that CRDL has no problem at all paying its short term obligations.
  • CRDL has a better Current ratio (3.89) than 90.63% of its industry peers.
  • A Quick Ratio of 3.89 indicates that CRDL has no problem at all paying its short term obligations.
  • CRDL's Quick ratio of 3.89 is amongst the best of the industry. CRDL outperforms 90.63% of its industry peers.
Industry RankSector Rank
Current Ratio 3.89
Quick Ratio 3.89
CRDL.CA Yearly Current Assets VS Current LiabilitesCRDL.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. CRDL.CA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 23.53% over the past year.
EPS 1Y (TTM)23.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • CRDL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.88% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-45.59%
EPS Next 2Y26.45%
EPS Next 3Y30%
EPS Next 5Y39.88%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CRDL.CA Yearly Revenue VS EstimatesCRDL.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M
CRDL.CA Yearly EPS VS EstimatesCRDL.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 0.5 -0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

1

4. CRDL.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CRDL. In the last year negative earnings were reported.
  • Also next year CRDL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRDL.CA Price Earnings VS Forward Price EarningsCRDL.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRDL.CA Per share dataCRDL.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CRDL's earnings are expected to grow with 30.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.45%
EPS Next 3Y30%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CRDL.CA Dividend Analysis

5.1 Amount

  • CRDL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CRDL.CA Fundamentals: All Metrics, Ratios and Statistics

CARDIOL THERAPEUTICS INC-A

TSX:CRDL (4/10/2026, 7:00:00 PM)

1.93

+0.05 (+2.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)04-01
Earnings (Next)05-12
Inst Owners20.04%
Inst Owner ChangeN/A
Ins Owners3.83%
Ins Owner ChangeN/A
Market Cap215.66M
Revenue(TTM)N/A
Net Income(TTM)-34.78M
Analysts82.5
Price Target9.59 (396.89%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.21%
Min EPS beat(2)-30.72%
Max EPS beat(2)18.3%
EPS beat(4)3
Avg EPS beat(4)12.55%
Min EPS beat(4)-30.72%
Max EPS beat(4)32.64%
EPS beat(8)5
Avg EPS beat(8)3.01%
EPS beat(12)9
Avg EPS beat(12)9.06%
EPS beat(16)13
Avg EPS beat(16)12.38%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 22.56
P/tB 22.56
EV/EBITDA N/A
EPS(TTM)-0.39
EYN/A
EPS(NY)-0.57
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS0
BVpS0.09
TBVpS0.09
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -268.65%
ROE -363.82%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-80.54%
ROA(5y)-81.5%
ROE(3y)-102.38%
ROE(5y)-100.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 22.17%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.89
Quick Ratio 3.89
Altman-Z 6.59
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)21.14%
Cap/Depr(5y)17.07%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.22%
EPS Next Y-45.59%
EPS Next 2Y26.45%
EPS Next 3Y30%
EPS Next 5Y39.88%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y5.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year23.92%
EBIT Next 3Y13.88%
EBIT Next 5Y17.79%
FCF growth 1Y12.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y12.36%
OCF growth 3YN/A
OCF growth 5YN/A

CARDIOL THERAPEUTICS INC-A / CRDL.CA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CARDIOL THERAPEUTICS INC-A (CRDL.CA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to CRDL.CA.


What is the valuation status of CARDIOL THERAPEUTICS INC-A (CRDL.CA) stock?

ChartMill assigns a valuation rating of 1 / 10 to CARDIOL THERAPEUTICS INC-A (CRDL.CA). This can be considered as Overvalued.


What is the profitability of CRDL stock?

CARDIOL THERAPEUTICS INC-A (CRDL.CA) has a profitability rating of 0 / 10.


Can you provide the financial health for CRDL stock?

The financial health rating of CARDIOL THERAPEUTICS INC-A (CRDL.CA) is 6 / 10.